BR0010923A - Processo para a produção de atorvastatina de cálcio amorfa - Google Patents

Processo para a produção de atorvastatina de cálcio amorfa

Info

Publication number
BR0010923A
BR0010923A BR0010923-1A BR0010923A BR0010923A BR 0010923 A BR0010923 A BR 0010923A BR 0010923 A BR0010923 A BR 0010923A BR 0010923 A BR0010923 A BR 0010923A
Authority
BR
Brazil
Prior art keywords
atorvastatin
solvent
calcium
production
atorvastatin calcium
Prior art date
Application number
BR0010923-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Yatendra Kumar
Rajesh Kumar Thaper
S M Dileep Kumar
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11091180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0010923(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of BR0010923A publication Critical patent/BR0010923A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0010923-1A 1999-05-25 2000-01-06 Processo para a produção de atorvastatina de cálcio amorfa BR0010923A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN775DE1999 IN191236B (cg-RX-API-DMAC7.html) 1999-05-25 1999-05-25
PCT/IB2000/000014 WO2000071116A1 (en) 1999-05-25 2000-01-06 Process for the production of amorphous atorvastatin calcium

Publications (1)

Publication Number Publication Date
BR0010923A true BR0010923A (pt) 2002-07-16

Family

ID=11091180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010923-1A BR0010923A (pt) 1999-05-25 2000-01-06 Processo para a produção de atorvastatina de cálcio amorfa

Country Status (15)

Country Link
US (2) US6528660B1 (cg-RX-API-DMAC7.html)
EP (1) EP1185264B1 (cg-RX-API-DMAC7.html)
CN (2) CN1680315A (cg-RX-API-DMAC7.html)
AT (1) ATE362759T1 (cg-RX-API-DMAC7.html)
AU (1) AU778962B2 (cg-RX-API-DMAC7.html)
BR (1) BR0010923A (cg-RX-API-DMAC7.html)
DE (1) DE60034946T2 (cg-RX-API-DMAC7.html)
DK (1) DK1185264T3 (cg-RX-API-DMAC7.html)
ES (1) ES2284472T3 (cg-RX-API-DMAC7.html)
HK (1) HK1045118A1 (cg-RX-API-DMAC7.html)
IN (1) IN191236B (cg-RX-API-DMAC7.html)
MY (1) MY133511A (cg-RX-API-DMAC7.html)
PT (1) PT1185264E (cg-RX-API-DMAC7.html)
WO (1) WO2000071116A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200109656B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
IN190564B (cg-RX-API-DMAC7.html) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
JP3965155B2 (ja) 2001-06-29 2007-08-29 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 結晶型［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β，δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）（アトロバスタチン）
AU2001284385A1 (en) * 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CA2520740C (en) * 2003-04-11 2012-06-05 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
DE602004016311D1 (de) * 2003-04-29 2008-10-16 Organon Nv Verfahren zur verfestigung, bei welchem ein anti-lösungsmittel benutzt wird
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
PL1727795T3 (pl) 2004-03-17 2012-06-29 Ranbaxy Laboratories Ltd Sposób wytwarzania soli wapniowej atorwastatyny w formie bezpostaciowej
US7241800B2 (en) * 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
KR100829268B1 (ko) * 2004-04-16 2008-05-13 화이자 프로덕츠 인코포레이티드 비정질 아토바스타틴 칼슘의 제조 방법
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
CA2833770A1 (en) * 2004-07-16 2006-01-26 Lek Pharmaceuticals D.D Oxidative degradation products of atorvastatin calcium
EP1771412A2 (en) 2004-07-20 2007-04-11 Warner-Lambert Company LLC Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
US7645888B2 (en) 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
DE05810535T1 (de) * 2004-10-18 2007-04-19 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von amorphem atorvastatin-hemi-calcium durch lösen des salzes in einem organischen lösungsmittel, bei dem es sich um eine mischung enes alkohols und eines ketons und/oder eines esters handelt, und entfernen des lösungsmittels
AU2005298383A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048888A1 (en) * 2004-11-01 2006-05-11 Jubilant Organosys Limited Novel process for the preparation of amorphous atorvastatin calcium salt
AU2005305460B2 (en) 2004-11-22 2011-04-21 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
WO2007052296A2 (en) * 2005-08-23 2007-05-10 Kopran Research Laboratories Ltd A process of preparing amorphous atorvastatin calcium
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US8084488B2 (en) * 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
JP2010534644A (ja) * 2007-07-27 2010-11-11 シプラ・リミテッド 医薬組成物およびその製造方法
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
CN101684090B (zh) * 2008-09-27 2012-12-05 广东东阳光药业有限公司 一种制备无定形阿托伐他汀钙的方法
US8115015B2 (en) 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
WO2016055934A1 (en) * 2014-10-09 2016-04-14 Glenmark Pharmaceuticals Limited Amorphous form of lomitapide mesylate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HU223599B1 (hu) * 1995-07-17 2004-10-28 Warner-Lambert Company I,II és IV kristályformájú [R-(R*,R*)]-2(4-fluor-fenil)-béta,delta-dihidroxi-5-(1-metil-etil)-3-fenil-4-[(fenil-amino)-karbonil]-1H-pirrol-1-heptánkarbonsav-hemikalciumsó-hidrát (atorvasztatin-hidrát) és a vegyületeket tartalmazó gyógyászati készítmények
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina

Also Published As

Publication number Publication date
CN1680315A (zh) 2005-10-12
ATE362759T1 (de) 2007-06-15
ZA200109656B (en) 2002-06-27
US6528660B1 (en) 2003-03-04
AU1996700A (en) 2000-12-12
ES2284472T3 (es) 2007-11-16
CN1196679C (zh) 2005-04-13
MY133511A (en) 2007-11-30
WO2000071116A1 (en) 2000-11-30
US20030149279A1 (en) 2003-08-07
DE60034946T2 (de) 2008-01-17
AU778962B2 (en) 2004-12-23
PT1185264E (pt) 2007-07-10
IN191236B (cg-RX-API-DMAC7.html) 2003-10-11
EP1185264A1 (en) 2002-03-13
DE60034946D1 (de) 2007-07-05
EP1185264B1 (en) 2007-05-23
DK1185264T3 (da) 2007-08-20
CN1351493A (zh) 2002-05-29
HK1045118A1 (zh) 2002-11-15

Similar Documents

Publication Publication Date Title
BR0010923A (pt) Processo para a produção de atorvastatina de cálcio amorfa
PT897386E (pt) Processo para a preparacao de um sal de magnesio de um heterociclo substituido com sulfinilo
EP1088792A4 (en) METHOD FOR CLEANING TURBID WATER
BR9106112A (pt) Processo para preparacao de solucao aquosa acida consistindo essencialmente de sal fosfomolibdovanadato dissolvido e processo para preparacao de sal de fosfomolibdovanadato solido
HUP0001547A2 (hu) Az S-omeprazol új formája
DZ3426A1 (fr) Procede de dessalement d'eau de mer
EA199900526A1 (ru) Применение производных 7-(2-окса-5,8-диазабицикло[4,3,0] нон-8-ил)-хинолонкарбоновой кислоты и -нафтиридонкарбоновой кислоты для лечения helicobacter pylori- инфекций и связанных с ними гастродуоденальных заболеваний
BR0008112A (pt) Agonistas de 5-ht 1f
PT1236728E (pt) Compostos de ester hidroxi-2-indolinilbutirico 2-substituido tipo s e processo para a sua preparacao
EP1277784A4 (en) METHOD FOR PURIFYING POLYARYL SULFIDES
BR9911137A (pt) Processo para tratamento de correntes de fluido
FR2647433B1 (fr) Procede de preparation par voie aqueuse de sulfate de calcium purifie
WO2000006173A8 (en) 5-ht1f agonists
DK0450420T3 (da) Heterocyclisk substituerede dihydropyridiner, fremgangsmåde til deres fremstilling og deres anvendelse i lægemidler
WO2000000490A3 (en) 5-ht1f agonists
BR9913858A (pt) Processo para a produção de um derivado de ácido carboxìlico de naftridina (sesquiidrato de metanossulfonato)
ID26210A (id) Proses pemurnian turunan sefalosporin
PT84819B (pt) Processo para a preparacao de compostos 2-piridil-penem
FR2779143B1 (fr) Procede ameliore de preparation d'un sel fondu
BR9911006A (pt) Purificação de carboxaldeìdo
BR9915028A (pt) Processo para preparação de 2-oxo-1,3-dioxolanas monohalo-genadas
AU2001236442A1 (en) Method for the purification of aryl sulfonic acids and salts
BR9814388A (pt) Processo para purificar uma solução de um éster pró-droga de ampicilina
PT1076646E (pt) Processo para a preparacao estereoquimicamente controlada de compostos azaciclicos muito substituidos isometricamente puros
FR2795723B1 (fr) Procede de preparation de sels de sulfonate via l'hydrolyse alcaline des chlorures de sulfonyle correspondants

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.